Gerresheimer’s 23% Rally Masks a Factory Closure and a BaFin Probe

Gerresheimer stock surges 23% but faces 20% downside risk from Barclays downgrade, Illinois plant closure, and a BaFin accounting probe.

Gerresheimer’s stock has surged nearly 23% over the past month, but the rally sits on shaky ground. Beneath the surface, the German packaging specialist is grappling with a plant closure, a regulatory investigation, and a brutal downgrade from Barclays that warns of a 20% downside from current levels.

The British bank’s analyst Jonathon Unwin cut his rating to “Underweight” on Tuesday, slashing the price target to €19. With shares trading around €23.80, the call implies a significant retreat. Unwin’s rationale is structural: he prefers makers of injection systems such as Ypsomed over traditional glass-container suppliers like Gerresheimer, whose core business revolves around vials and ampoules.

Illinois plant shuttered, 172 jobs cut

The company is already acting on that pressure. Gerresheimer will close its glass plant in Chicago Heights, Illinois, by September 30, eliminating 172 positions. Production of pharmaceutical specialty glass — serum bottles and infusion flasks — will shift to existing facilities in Italy and India. A company spokesperson described the move as part of a global cost-cutting programme aimed at improving capacity utilisation and profitability.

The restructuring leaves a deep imprint on the balance sheet. Management expects impairment charges of between €220 million and €240 million for the 2025 financial year. These non-cash write-downs relate primarily to the US glass business and technology projects at the Sensile Medical subsidiary.

BaFin probe deepens the fog

Operational cuts are only one front in a multi-layered crisis. Germany’s financial regulator BaFin is conducting a special audit into the company’s accounting practices. The parallel investigation by the audit oversight body into KPMG — which issued an unqualified audit opinion for the flawed 2024 accounts — adds another layer of scrutiny.

The regulatory cloud has already forced Gerresheimer to postpone its annual report for 2025 to June 2026. The annual general meeting has been cancelled, and the first-quarter 2026 report is delayed. Creditors have shown some patience: they extended the deadline for audited 2025 figures to September 2026.

A narrow path to clarity

The market’s attention now fixes on June, when the delayed annual report is due. Investors will be looking for clarity on the company’s equity base and its ability to pay dividends. If management fails to provide credible answers, the stock — already down nearly 60% over the past year — risks sliding back toward the February low of €15.57.

Despite the turmoil, the board has issued a forecast for 2026, projecting revenue of €2.3 billion to €2.4 billion and an adjusted operating margin of roughly 18% to 19%. Those targets are conditional on the outcome of the pending audits. No date has been set for the publication of the BaFin findings.

On a brighter operational note, partner SQ Innovation secured CE marking for the jointly developed Lasix-ONYU system, a home-therapy device that also received European Medicines Agency approval for a centralised authorisation process. Yet the regulatory and accounting uncertainties continue to dominate the narrative, leaving the share price hostage to events beyond management’s immediate control.